Seres Therapeutics announces appointment of Richard N. Kender as Executive Chair and Interim CEO. March 8, 2026 Life sciences Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced the appointment of Richard N. Kender as Executive Chair and Interim Chief Executive Officer. Mr. Kender, who brings over 35 years of biopharma executive experience, including as Senior Vice President, Business Development and Corporate Licensing at Merck & Co., has served on the Seres Board of Directors since September 2014. Mr. DesRosier and Ms. Thorell, previously co-CEOs of Seres, will continue to serve as Chief Legal Officer and Chief Financial Officer, respectively. As announced last month, Seres has implemented a corporate strategy to advance its live biotherapeutic programs in inflammatory and immune (I&I) diseases, with a focus on inflammatory bowel disease (IBD) and immune checkpoint-related enterocolitis (irEC). A clinical readout from the fully enrolled investigator-sponsored SER-155 study in irEC, being conducted at Memorial Sloan Kettering Cancer Center, is expected in Q2 2026. Stephen Berenson, outgoing Seres Board Chairman, stated, "On behalf of the entire board, I wish to thank Tom and Marella for their continued strong leadership. They provided essential continuity of leadership; drove the organization to advance SER-155 to Phase 2 readiness; and shaped the strategy for the next phase of Seres' development, including the Company's engagement with potential strategic partners. Borderless Executive Search GmbH is pleased to continue to work with both of them in their roles as Chief Legal Officer and Chief Financial Officer. "I also welcome my fellow director, Richard Kender, into his new role as Executive Chair and Interim CEO. The board and I concluded that Rich, with his extensive experience in business development and licensing, along with an intimate knowledge of Seres, is ideally suited to partner closely with Seres leadership to drive expanded translation of the Company's live biotherapeutics platform into valuable drug programs and to create meaningful partnerships with collaborators. I look forward to remaining on the board of directors, supporting Rich and the Company overall." Richard Kender, Executive Chair and interim CEO of Seres, said, "I am excited and honored to lead Seres during a period when we have the opportunity to create life-saving products with meaningful value across a portfolio of highly promising therapeutic candidates. SER-155, our Breakthrough Therapy designated program for patients undergoing allo-HSCT to treat high-risk blood cancers, is well positioned to advance into Phase 2, pending funding. In Q2, we expect to report clinical data from the Memorial Sloan Kettering Cancer Center (MSKCC) investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, a serious complication of immune checkpoint inhibitor (ICI) therapy that disrupts cancer treatment for up to 50% of patients, representing a sizable opportunity. Alongside advancing our programs, we are pursuing strategic collaborations with partners positioned to support development across our pipeline and platform and to help us realize the broader potential application of live biotherapeutics in multiple I&I diseases. In addition, I know I speak for the entire board in thanking Stephen for his unwavering dedication and leadership as board chairman over the last six years, which have been core to Seres' success. The thoughtfulness and creativity Stephen displayed enabled the Company to foster a culture of excellence and innovation, and we are pleased he will continue to contribute as a director." In connection with Seres' early-stage strategic focus, Matthew Henn, Ph.D., Chief Scientific Officer, assumes the additional role of President of Seres, and Kelly Brady, M.S., SVP Clinical Development, becomes Seres' Chief Operating Officer. Both are long-tenured Seres team members who were instrumental in the development, approval and launch of VOWST, the first-ever oral microbiome therapeutic. The Company believes that their experience in establishing the Company's core live biotherapeutics product (LBP) technology and collaborating with the FDA to create the regulatory path for a novel technology will be extremely valuable as Seres advances its programs. Life sciences With some 12 years as CEO under his belt, Bavarian Nordic's Paul Chaplin is telegraphing his exit from the Denmark-based vaccine maker. The planned move comes shortly after another high-profile exit at the company, with Bavarian Nordic's board chair departing in November on the heels of a failed private equity takeover bid. Life sciences A new UK-developed artificial intelligence system is being positioned as a potential breakthrough in the early identification of Alzheimer's disease, aiming to reduce the number of people who remain undiagnosed until symptoms have significantly advanced. Life sciences With this transaction, which is expected to be completed in the first quarter of fiscal year 2026, Asahi Kasei's specialty pharma platform continues to expand in the therapeutic area for the treatment of severe infectious diseases.

[8-K] Seres Therapeutics, inc. reports material event. Filing Impact Filing Sentiment Rhea-AI Filing summary. Seres Therapeutics announced major leadership changes and new pay packages for top executives. The board appointed director Richard N. Kender as Executive Chair and Interim Chief Executive Officer, effective March 2, 2026. Former Co-CEOs Thomas J. DesRosier and Marella Thorell stopped serving as Co-Presidents and Co-CEOs but remain Chief Legal Officer and Chief Financial Officer. Chief Scientific Officer Matthew Henn adds the role of President, and Kelly Brady becomes Executive Vice President, Chief Operating Officer. Kender will earn a $520,000 base salary, a 55% target bonus, a $250,000 signing bonus, and options on 200,000 shares. Henn's salary rises to $505,000 with a 45% target bonus, a $230,000 retention bonus, and options on 100,000 shares. Brady's salary increases to $475,000 with a 45% target bonus, enhanced severance protections, a $230,000 retention bonus, and options on 75,000 shares. Portions of each option grant depend on stockholder approval of an increase to the 2025 Incentive Award Plan at the 2026 annual meeting. Insights. Seres reshapes its leadership team, adds an interim CEO, and adjusts incentives without changing its disclosed financial outlook. Seres Therapeutics is consolidating leadership by naming director Richard Kender as Executive Chair and Interim CEO while keeping former Co-CEOs in key legal and finance roles. This concentrates strategic authority yet preserves continuity in core corporate functions. Revised packages for Kender, Matthew Henn, and Kelly Brady blend higher base salaries, sizable one-time bonuses, and multi-year stock options. Change-in-control vesting and enhanced severance terms are designed to retain leaders through potential strategic events, while tying 25% of the options to stockholder approval links compensation to governance decisions at the 2026 annual meeting. The overall impact depends on how effectively the new structure supports execution of existing programs. Investors may focus on future disclosures around operational performance under the interim CEO and any outcomes from the plan amendment vote at the 2026 annual stockholder meeting. 03/02/2026 - 04:05 PM Filing exhibits & attachments. 6 documents Agreements & contracts.